Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRN-22
- Development stage
- Preclinical
- Lead developer
- Sirana Pharma
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
SRN-22 is a preclinical-stage antisense oligonucleotide (ASO) developed by Sirana Pharma for the treatment of Osteogenesis Imperfecta (OI), a genetic disorder characterized by fragile bones. The therapeutic candidate utilizes Sirana's proprietary Musculoskeletal Targeting Technology (MTT), which conjugates the ASO to a bone-targeting peptide (typically a sequence of aspartic acid residues) to facilitate selective delivery to bone tissue. This targeted approach is designed to increase the local concentration of the drug in the skeleton while minimizing systemic off-target effects. SRN-22 aims to modulate the expression of specific genetic regulators of bone metabolism to improve bone mineral density and skeletal integrity in patients with OI.
- Other names
- SRN-22SRN22SRN 22
Beyond the preview
Go deeper on SRN-22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRN-22.